Literature DB >> 33511569

Impact of Physicians' Personalities and Behavioral Traits on Treatment-Related Decision-making for Elderly Acute Myeloid Leukemia.

Xia Wu1, Yi-Nan Jiang2, Yue-Lun Zhang3, Jia Chen1, Yue-Ying Mao1, Lu Zhang1, Dao-Bin Zhou1, Xin-Xin Cao4, Jian Li5.   

Abstract

BACKGROUND: Elderly patients with acute myeloid leukemia (AML) can be treated with intensive therapy, low-intensity therapy, or best supportive care. Medical decision-making might be affected by physicians' occupational and non-occupational factors.
OBJECTIVE: To explore the impact of physicians' personalities and behavioral traits on treatment-related decision-making for elderly AML patients.
DESIGN: A nationwide cross-sectional survey. PARTICIPANTS: Hematologists in mainland China (N = 529; response rate 64.5%). MAIN MEASURES: The medical decision-making for elderly AML patients was evaluated using 6 clinical vignettes. Hematologists' attitudes toward risk and uncertainty, Big Five personality traits, and decision-making styles were assessed using binary lottery choices and well-recognized self-report inventories. KEY
RESULTS: The resulting binary regression model in predicting treatment intensity contained professional title group (OR = 0.012, 95% CI 0.001 to 0.136, P < 0.001), conscientiousness (OR = 0.336, 95% CI 0.121 to 0.932, P = 0.036), extraversion (OR = 0.403, 95% CI 0.166 to 0.974, P = 0.044), conscientiousness by title group (OR = 2.009, 95% CI 1.100 to 3.667, P = 0.023), and extraversion by title group (OR = 1.627, 95% CI 0.965 to 2.743, P = 0.068) as predictors of therapy intensity preference. Junior physicians with a higher level of extraversion (mean difference = 0.27; 95% CI 0.07 to 0.45; P = 0.009) or conscientiousness (mean difference = 0.19; 95% CI 0.01 to 0.36; P = 0.028) tended to prescribe more intensive therapy. Meanwhile, no significant correlation was found between physicians' personalities or behavioral traits and treatment-related decision-making in senior physicians.
CONCLUSIONS: Physicians' personalities contribute to treatment-related decision-making for elderly AML patients, depending on the professional titles. More extravert or conscientious attending physicians tended to prescribe more intensive therapy. Meanwhile, the decisions made by chief and associate chief physicians were not impacted by their personal traits. Junior physicians should be aware of such potential influence when making medical decisions.
© 2021. Society of General Internal Medicine.

Entities:  

Keywords:  elderly acute myeloid leukemia; personality; physician; treatment-related decision-making

Mesh:

Year:  2021        PMID: 33511569      PMCID: PMC8481415          DOI: 10.1007/s11606-020-06467-w

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   6.473


  22 in total

1.  Physicians' diagnostic accuracy, confidence, and resource requests: a vignette study.

Authors:  Ashley N D Meyer; Velma L Payne; Derek W Meeks; Radha Rao; Hardeep Singh
Journal:  JAMA Intern Med       Date:  2013-11-25       Impact factor: 21.873

Review 2.  Selecting initial treatment of acute myeloid leukaemia in older adults.

Authors:  Nikolai A Podoltsev; Maximilian Stahl; Amer M Zeidan; Steven D Gore
Journal:  Blood Rev       Date:  2016-10-08       Impact factor: 8.250

Review 3.  Insights on practice variations in the management of lymphoma and leukemia.

Authors:  Fausto R Loberiza; Andrew C Cannon; Anthony J Cannon; Philip J Bierman
Journal:  Leuk Lymphoma       Date:  2014-03-07

4.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

5.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

6.  Cross-sectional survey: risk-averse French general practitioners are more favorable toward influenza vaccination.

Authors:  Sophie Massin; Bruno Ventelou; Antoine Nebout; Pierre Verger; Céline Pulcini
Journal:  Vaccine       Date:  2014-12-26       Impact factor: 3.641

7.  Impact of Patient-Provider Race, Ethnicity, and Gender Concordance on Cancer Screening: Findings from Medical Expenditure Panel Survey.

Authors:  Jyoti Malhotra; David Rotter; Jennifer Tsui; Adana A M Llanos; Bijal A Balasubramanian; Kitaw Demissie
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-10-11       Impact factor: 4.254

8.  Exploring physiotherapists' personality traits that may influence treatment outcome in patients with chronic diseases: a cohort study.

Authors:  Elisah Margretha Buining; Margit K Kooijman; Ilse C S Swinkels; Martijn F Pisters; Cindy Veenhof
Journal:  BMC Health Serv Res       Date:  2015-12-16       Impact factor: 2.655

9.  Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey.

Authors:  Pierre Bories; Sébastien Lamy; Célestine Simand; Sarah Bertoli; Cyrille Delpierre; Sandra Malak; Luc Fornecker; Stéphane Moreau; Christian Récher; Antoine Nebout
Journal:  Haematologica       Date:  2018-07-13       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.